RODEN MATTHEW enters AKTIS ONCOLOGY, INC. with 92K shares plus derivative instruments
Holding both equity and derivatives at entry signals strong long-term conviction in the company.
Direct Derivatives
Filed: 1/8/2026ACC: 0001193125-26-008065
DirectorOfficer· President and CEO
Since Jan 2026
92K
Baseline shares
100% direct
92K
Direct ownership
1 position
2.15M
Derivative underlying
4 instruments
1
Security positions
All direct
Non-Derivative Holdings1
Common Stock
DirectShares owned92K
Total
92K direct92K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 92K | Direct |
| Total | 92K | 92K direct |
Derivative Holdings4
Stock Option (Right to Buy)
DirectUnderlying security
Common Stock
Underlying shares
618.76K
Shares owned
N/A
Exercise price
9.33
Expiration
—
Exercise window
—
Stock Option (Right to Buy)
DirectUnderlying security
Common Stock
Underlying shares
578.28K
Shares owned
N/A
Exercise price
1.91
Expiration
—
Exercise window
—
Stock Option (Right to Buy)
DirectUnderlying security
Common Stock
Underlying shares
558.10K
Shares owned
N/A
Exercise price
3.66
Expiration
—
Exercise window
—
Stock Option (Right to Buy)
DirectUnderlying security
Common Stock
Underlying shares
394.28K
Shares owned
N/A
Exercise price
18.00
Expiration
—
Exercise window
—
Total
Underlying
2.15M
Owned
0.00
| Security | Underlying | Exercise Price | Exercise Window | Expiration | Underlying Shares | Shares Owned |
|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock | 9.33 | — | — | 618.76K | N/A |
| Stock Option (Right to Buy) Direct | Common Stock | 1.91 | — | — | 578.28K | N/A |
| Stock Option (Right to Buy) Direct | Common Stock | 3.66 | — | — | 558.10K | N/A |
| Stock Option (Right to Buy) Direct | Common Stock | 18.00 | — | — | 394.28K | N/A |
| Total | 2.15M | 0.00 | ||||